Evotec Investor Day Presentation Deck
evotec
PAGE 27
INSULIN
oo
> 7% of population ¹)2);
> 20 US$ bn today -
tremendous potential³)4)
Paradigm shift for cure
Current insulin therapy versus beta cell therapy
Old paradigm
Insulin injections do not address
underlying cause of disease.
-
• Therapy dominates daily life
• Glucose measurements
Hypoglycemic episodes
Kidney failure
• Blindness
• Stroke
Amputation
¹) Norris et al., Lancet Diabetes Endocrinol 2020; 226-38; Chatterjee et al., Lancet 2017; 389: 2239-51
2) Globaldata list more than 500 companies active in diabetes (count includes affiliates or large pharma companies)
3) Insulin and its analogues, with or without additional technical devices like pumps, closed loop systems, etc.
QRbeta
THERAPEUTICS
New paradigm
Beta cell therapy
Beta cell implant or infusion
• Significant improvement in
quality of life
• No blood glucose measurements
• No daily insulin injections
• No hypoglycemic episodes
• No diabetic complications
Nerve damage, kidney damage,
blindness, ...
4) Global data, EU5, USA and Japan, patients 20 - 64 year old;
Accumulated sales of top 10 Diabetes products in 2018View entire presentation